



Docket No. ORT-1451

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Dyatkin et al.

Serial No. : 09/891,602

Art Unit: 1625

Filed : June 26, 2001

Examiner: C. Aulakh

For : AZA BRIDGED BICYCLIC AMINO ACID DERIVATIVES

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Mail Stop RCE, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

February 9, 2004
(Date of Deposit)

Hal B. Woodrow
(Name of applicant, assignee, or Registered Representative)

Hal Bunt Woodrow
(Signature)

February 9, 2004
(Date of Signature)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e)
(attached); or

☐ Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth
in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

☐ Statement in Accordance with §1.97(e)
(attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the

national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

☐ There are no listed references which are not in the English language.

☒ The relevance of those listed references which are not in the English language can be found in an English-language Abstract contained therein.

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT1451/HBW. This form is submitted in triplicate.

Respectfully submitted,

Hal Brent Woodrow
Hal B. Woodrow
Reg. No. 32,501
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2976
DATED: February 9, 2004



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 6

Application Number	09/891,602
Filing Date	June 26, 2001
First Named Inventor	Dyatkin et al.
Group Art Unit	1625
Examiner Name	Aulakh, C.
Attorney Docket Number	ORT-1451

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		6,521,666	B1	Sircar et al.	2-18-2003	
		6,534,513	B1	Porter et al.	3-18-2003	
		2002/0086882	A1	Konradi et al.	7-04-2002	
		2002/0091115	A1	Dyatkin et al.	7-11-2002	
		2002/0137935	A1	Head et al.	9-26-2002	
		2003/0018195	A1	Konradi et al.	1-23-2003	
		2003/0027771	A1	Dressen et al.	2-06-2003	
		2003/0027850	A1	Ashwell et al.	2-06-2003	
		6,407,066	B1	Dressen et al.	6-18-2002	
		6,455,550		Chen et al.	9-24-2002	
		6,229,011		Chen et al.	5-08-2001	
		2002/0133015	A1	Kaplan et al.	9-19-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
		WO	99/06435	A1	Athena Neurosciences, Inc.	2-11-1999		
		WO	01/21584	A1	Genentech, Inc.	3-29-2001		
		WO	03/010135	A1	Toshihiko et al.	2-06-2003	w/English-language Abstract	
		WO	02/16329	A1	Ajinomoto KK	3-05-2003	w/English-language Abstract	
		WO	01/32610	A1	Kaken Pharma Co. Ltd.	5-10-2001	w/English-language Abstract	
		WO	99/36393	A1	Tanabe Seiyaku Co., Ltd.	7-22-1999		
		WO	01/28830	A1	Ajinomoto KK	7-02-2003	w/English-language Abstract	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 6

Application Number	09/891,602
Filing Date	June 26, 2001
First Named Inventor	Dyatkin et al.
Group Art Unit	1625
Examiner Name	Aulakh, C.
Attorney Docket Number	ORT-1451

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		6,291,511	B1	Durette et al.	9-18-2002	
		6,579,889	B2	de Laszlo et al.	6-17-2003	
		6,291,511	B1	Durette et al.	9-18-2001	
		6,403,584	B1	de Laszlo et al.	6-11-2002	
		6,426,348	B1	Hull et al.	7-30-2002	
		6,191,171	B1	DeLaszlo et al.	2-20-2001	
		6,420,418	B1	Hagmann et al.	7-16-2002	
		6,353,099	B1	DeLaszlo et al.	3-05-2002	
		6,221,888	B1	Durette et al.	4-24-2001	
		3,905,971		Miller	9-16-1975	
		6,559,174	B2	Lin et al.	5-06-2003	
		6,479,666	B2	Hull et al.	11-12-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
		WO	02/057242	A2	Almirall Prodesfarma, S.A.	7-25-2002		
		WO	01/36376	A1	Ajinomoto Co., Inc.	8-21-2002	w/English-language Abstract	
		WO	01/54690	A1	Biogen, Inc.	8-02-2001		
		WO	02/22563	A1	Toray Industries	7-02-2003	w/English-language Abstract	
		WO	02/08202	A2	Elan Pharmaceuticals, Inc.	1-31-2002		
		WO	02/16329	A1	Ajinomoto KK	3-05-2003	w/English-language Abstract	
		WO	00/18759	A1	Celltech Therapeutics Limited	4-06-2000		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 3 of 6	Application Number	09/891,602
	Filing Date	June 26, 2001
	First Named Inventor	Dyatkin et al.
	Group Art Unit	1625
	Examiner Name	Aulakh, C.
	Attorney Docket Number	ORT-1451

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		2003/0100585	A1	Duplantier et al.	5-29-2003	
		2003/0130166	A1	Cunningham	7-10-2003	
		2002/0197233	A1	Relton et al.	12-26-2002	
		2002/0019402	A1	Dominguez et al.	2-14-2002	
		6,479,519	B1	Astles et al.	11-12-2002	
		6,469,036	B1	Costanzo et al.	10-22-2002	
		5,523,308		Costanzo et al.	6-04-1996	
		5,827,866		Costanzo et al.	10-27-1998	
		5,827,860		Costanzo et al.	10-27-1998	
		5,525,623		Spear et al.	6-11-1996	
		5,034,391		Blaschke et al.	7-23-1991	

FOREIGN PATENT DOCUMENTS


Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
		WO	00/18759	A1	Celltech Therapeutics Limited	4-06-2000		
		WO	00/01690	A1	Celltech Therapeutics Limited	1-13-2000		
		WO	99/61465	A1	Celltech Therapeutics Limited	12-02-1999		
		WO	99/643900	A1	Celltech Therapeutics Limited	12-16-1999		
		WO	99/48879	A1	Celltech Therapeutics Limited	9-30-1999		
		WO	99/43642	A1	Celltech Therapeutics Limited	9-02-1999		
		WO	99/35163	A1	Celltech Therapeutics Limited	7-15-1999		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

• Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for H.R. 1449A/PTO

(use as many sheets as necessary)

Sheet 4 of 6

<i>Application Number</i>	09/891,602
<i>Filing Date</i>	June 26, 2001
<i>First Named Inventor</i>	Dyatkin et al.
<i>Group Art Unit</i>	1625
<i>Examiner Name</i>	Aulakh, C.
<i>Attorney Docket Number</i>	ORT-1451

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
		WO	00/20396	A1	Celltech Therapeutics Limited	4-13-2000		
		WO	99/10313	A1	F. Hoffmann-La Roche AG	3-04-1999		
		WO	99/10312	A1	F. Hoffmann-La Roche AG	3-04-1999		
		WO	01/42225	A2	F. Hoffmann-La Roche AG	6-14-2001		
		WO	01/42215	A1	F. Hoffmann-La Roche AG	6-14-2001		
		WO	99/23063	A1	Rhone-Poulenc Rorer Limited	5-14-1999		
		WO	01/14328	A2	Merck & Co. Inc.	3-01-2001		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substantive 1449A/PTO

(use as many sheets as necessary)

Sheet 5 of 6

Application Number	09/891,602
Filing Date	June 26, 2009
First Named Inventor	Dyatkin et al.
Group Art Unit	1625
Examiner Name	Aulakh, C.
Attorney Docket Number	ORT-1451

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

to a collection of information unless it displays a valid OMB control number.

Substitute for form M-494P TO

(use as many sheets as necessary)

Sheet 6 of 6

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.